Co-targeting c-Met and DNA double-strand breaks (DSBs): Therapeutic strategies in BRCA-mutated gastric carcinomas.

[1]  A. Kent,et al.  Gastrointestinal tumours , 2018, Oxford Medicine Online.

[2]  S. Staibano,et al.  USP7 inhibitors, downregulating CCDC6, sensitize lung neuroendocrine cancer cells to PARP-inhibitor drugs. , 2017, Lung cancer.

[3]  J. Ying,et al.  MET overexpression, gene amplification and relevant clinicopathological features in gastric adenocarcinoma , 2016, Oncotarget.

[4]  A. Celetti,et al.  Use of poly ADP-ribose polymerase [PARP] inhibitors in cancer cells bearing DDR defects: the rationale for their inclusion in the clinic , 2016, Journal of experimental & clinical cancer research : CR.

[5]  Ignace Vergote,et al.  Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer. , 2016, The New England journal of medicine.

[6]  A. Chakraborty,et al.  Classical non-homologous end-joining pathway utilizes nascent RNA for error-free double-strand break repair of transcribed genes , 2016, Nature Communications.

[7]  T. Oyama,et al.  High Expression of MRE11-RAD50-NBS1 Is Associated with Poor Prognosis and Chemoresistance in Gastric Cancer. , 2016, Anticancer research.

[8]  Y. Bang,et al.  gastrointestinal tumours, non-colorectalOlaparib in combination with paclitaxel in patients with advanced gastric cancer who have progressed following first-line therapy: Phase III GOLD study , 2016 .

[9]  K.-Y. Choi,et al.  Spin–orbit coupled molecular quantum magnetism realized in inorganic solid , 2016, Nature Communications.

[10]  W. Yong,et al.  ATM Expression Predicts Veliparib and Irinotecan Sensitivity in Gastric Cancer by Mediating P53-Independent Regulation of Cell Cycle and Apoptosis , 2016, Molecular Cancer Therapeutics.

[11]  S. Tomao,et al.  Update on Poly-ADP-ribose polymerase inhibition for ovarian cancer treatment , 2016, Journal of Translational Medicine.

[12]  J. Yélamos,et al.  Understanding specific functions of PARP-2: new lessons for cancer therapy. , 2016, American journal of cancer research.

[13]  M. Shah,et al.  A Randomized Phase II Study of FOLFOX With or Without the MET Inhibitor Onartuzumab in Advanced Adenocarcinoma of the Stomach and Gastroesophageal Junction. , 2016, The oncologist.

[14]  R. Kanthan,et al.  Gastric biomarkers: a global review , 2016, World Journal of Surgical Oncology.

[15]  A. Davis,et al.  Unsolved mystery: the role of BRCA1 in DNA end-joining , 2016, Journal of radiation research.

[16]  Liping Yu,et al.  Small-molecule inhibitors identify the RAD52-ssDNA interaction as critical for recovery from replication stress and for survival of BRCA2 deficient cells , 2016, eLife.

[17]  R. Langer,et al.  Depletion of FOXM1 via MET Targeting Underlies Establishment of a DNA Damage-Induced Senescence Program in Gastric Cancer. , 2016, Clinical cancer research : an official journal of the American Association for Cancer Research.

[18]  P. Zhou,et al.  Emerging molecular classifications and therapeutic implications for gastric cancer , 2016, Chinese journal of cancer.

[19]  R. Langer,et al.  Depletion of FOXM1 via MET Targeting Underlies Establishment of a DNA Damage–Induced Senescence Program in Gastric Cancer , 2016, Clinical Cancer Research.

[20]  L. Pearl,et al.  The Ku-binding motif is a conserved module for recruitment and stimulation of non-homologous end-joining proteins , 2016, Nature Communications.

[21]  A. Ozet,et al.  Advances of Molecular Targeted Therapy in Gastric Cancer , 2016, Journal of Gastrointestinal Cancer.

[22]  E. Smyth,et al.  Novel targets in the treatment of advanced gastric cancer: a perspective review , 2016, Therapeutic advances in medical oncology.

[23]  T. Skorski,et al.  Targeting BRCA1- and BRCA2-deficient cells with RAD52 small molecule inhibitors , 2016, Nucleic acids research.

[24]  T. Mok,et al.  MET Amplification and Exon 14 Splice Site Mutation Define Unique Molecular Subgroups of Non–Small Cell Lung Carcinoma with Poor Prognosis , 2016, Clinical Cancer Research.

[25]  Hyung Rae Kim,et al.  Novel c-Met inhibitor suppresses the growth of c-Met-addicted gastric cancer cells , 2016, BMC Cancer.

[26]  Chien-Liang Liu,et al.  Blocking c-Met-mediated PARP1 phosphorylation enhances anti-tumor effects of PARP inhibitors , 2016, Nature Medicine.

[27]  A. Jakubowska,et al.  BRCA1 founder mutations do not contribute to increased risk of gastric cancer in the Polish population , 2016, Hereditary cancer in clinical practice.

[28]  N. Lu,et al.  Molecular targeted therapy for the treatment of gastric cancer , 2016, Journal of experimental & clinical cancer research : CR.

[29]  Ken Kato,et al.  Serum level of hepatocyte growth factor is a novel marker of predicting the outcome and resistance to the treatment with trastuzumab in HER2-positive patients with metastatic gastric cancer , 2015, Oncotarget.

[30]  Kazuyuki Kojima,et al.  Clinical significance of MET in gastric cancer. , 2015, World journal of gastrointestinal oncology.

[31]  S. Kwon,et al.  Tumor suppressive effect of PARP1 and FOXO3A in gastric cancers and its clinical implications , 2015, Oncotarget.

[32]  G. Iliakis,et al.  Alternative end-joining repair pathways are the ultimate backup for abrogated classical non-homologous end-joining and homologous recombination repair: Implications for the formation of chromosome translocations. , 2015, Mutation research. Genetic toxicology and environmental mutagenesis.

[33]  Serena Nik-Zainal,et al.  A mutational signature in gastric cancer suggests therapeutic strategies , 2015, Nature Communications.

[34]  K. Nathanson,et al.  DCIS in BRCA1 and BRCA2 mutation carriers: prevalence, phenotype, and expression of oncodrivers C-MET and HER3 , 2015, Journal of Translational Medicine.

[35]  K. Sudo,et al.  Advancing pharmacological treatment options for advanced gastric cancer , 2015, Expert opinion on pharmacotherapy.

[36]  F. Roviello,et al.  c-Met targeting in advanced gastric cancer: An open challenge. , 2015, Cancer letters.

[37]  Joon-Oh Park,et al.  Randomized, Double-Blind Phase II Trial With Prospective Classification by ATM Protein Level to Evaluate the Efficacy and Tolerability of Olaparib Plus Paclitaxel in Patients With Recurrent or Metastatic Gastric Cancer. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[38]  Junjie Chen,et al.  Cell cycle-dependent inhibition of 53BP1 signaling by BRCA1 , 2015, Cell Discovery.

[39]  K. Rogers,et al.  The role of BRCA1 and BRCA2 mutations in prostate, pancreatic and stomach cancers , 2015, Hereditary cancer in clinical practice.

[40]  A. Corvalán,et al.  Molecular classification of gastric cancer: Towards a pathway-driven targeted therapy , 2015, Oncotarget.

[41]  M. Shah,et al.  METGastric: A phase III study of onartuzumab plus mFOLFOX6 in patients with metastatic HER2-negative (HER2-) and MET-positive (MET+) adenocarcinoma of the stomach or gastroesophageal junction (GEC). , 2015 .

[42]  C. Scott,et al.  Poly (ADP-ribose) polymerase inhibitors: recent advances and future development. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[43]  Jason G. Jin,et al.  Molecular analysis of gastric cancer identifies subtypes associated with distinct clinical outcomes , 2015, Nature Medicine.

[44]  Yilong Zhang,et al.  Rilotumumab Exposure–Response Relationship in Patients with Advanced or Metastatic Gastric Cancer , 2015, Clinical Cancer Research.

[45]  Kyle M. Miller,et al.  Mammalian polymerase θ promotes alternative NHEJ and suppresses recombination , 2015, Nature.

[46]  Alan Ashworth,et al.  Synthetic lethality and cancer therapy: lessons learned from the development of PARP inhibitors. , 2015, Annual review of medicine.

[47]  Lihe Zhang,et al.  c-Met Targeting Enhances the Effect of Irradiation and Chemical Agents against Malignant Colon Cells Harboring a KRAS Mutation , 2014, PloS one.

[48]  Jason G. Jin,et al.  Genomic landscape and genetic heterogeneity in gastric adenocarcinoma revealed by whole-genome sequencing , 2014, Nature Communications.

[49]  R. Donehower,et al.  Rilotumumab in combination with epirubicin, cisplatin, and capecitabine as first-line treatment for gastric or oesophagogastric junction adenocarcinoma: an open-label, dose de-escalation phase 1b study and a double-blind, randomised phase 2 study. , 2014, The Lancet. Oncology.

[50]  G. Kroemer,et al.  Predictive biomarkers for cancer therapy with PARP inhibitors , 2014, Oncogene.

[51]  J. Gautier,et al.  DNA double-strand break repair pathway choice and cancer. , 2014, DNA repair.

[52]  Qi Li,et al.  MET inhibitor PHA-665752 suppresses the hepatocyte growth factor-induced cell proliferation and radioresistance in nasopharyngeal carcinoma cells. , 2014, Biochemical and biophysical research communications.

[53]  C. Maroun,et al.  The Met receptor tyrosine kinase: a key player in oncogenesis and drug resistance. , 2014, Pharmacology & therapeutics.

[54]  S. Akinaga,et al.  A phase II trial of a selective c-Met inhibitor tivantinib (ARQ 197) monotherapy as a second- or third-line therapy in the patients with metastatic gastric cancer , 2014, Investigational New Drugs.

[55]  K. O'Byrne,et al.  Chemotherapeutic Compounds Targeting the DNA Double-Strand Break Repair Pathways: The Good, the Bad, and the Promising , 2014, Front. Oncol..

[56]  A. Paradiso,et al.  Expression of base excision repair key factors and miR17 in familial and sporadic breast cancer , 2014, Cell Death and Disease.

[57]  T. Vuong,et al.  Effects of dna-dependent protein kinase inhibition by NU7026 on dna repair and cell survival in irradiated gastric cancer cell line N87. , 2014, Current oncology.

[58]  D. Aebersold,et al.  The Molecular Crosstalk between the MET Receptor Tyrosine Kinase and the DNA Damage Response — Biological and Clinical Aspects , 2013, Cancers.

[59]  Jun Lu,et al.  cMET as a potential therapeutic target in gastric cancer (Review). , 2013, International journal of molecular medicine.

[60]  Min Huang,et al.  Yhhu3813 is a novel selective inhibitor of c-Met Kinase that inhibits c-Met-dependent neoplastic phenotypes of human cancer cells , 2013, Acta Pharmacologica Sinica.

[61]  D. Cunningham,et al.  RILOMET-1: An international phase III multicenter, randomized, double-blind, placebo-controlled trial of rilotumumab plus epirubicin, cisplatin, and capecitabine (ECX) as first-line therapy in patients with advanced MET-positive gastric or gastroesophageal junction (G/GEJ) adenocarcinoma. , 2013 .

[62]  David J. Chen,et al.  DNA double strand break repair via non-homologous end-joining. , 2013, Translational cancer research.

[63]  Naoki Miyamoto,et al.  A Novel Inhibitor of c-Met and VEGF Receptor Tyrosine Kinases with a Broad Spectrum of In Vivo Antitumor Activities , 2013, Molecular Cancer Therapeutics.

[64]  P. Bonate,et al.  Phase II Study Evaluating 2 Dosing Schedules of Oral Foretinib (GSK1363089), cMET/VEGFR2 Inhibitor, in Patients with Metastatic Gastric Cancer , 2013, PloS one.

[65]  D. Shin,et al.  Bevacizumab (bev) in combination with capecitabine (cape) for the first-line treatment of elderly patients with metastatic colorectal cancer (mCRC): Results of a randomized international phase III trial (AVEX). , 2013 .

[66]  K. Nishio,et al.  MET amplification as a potential therapeutic target in gastric cancer , 2012, Oncotarget.

[67]  Demin Zhou,et al.  c-Met inhibitor SU11274 enhances the response of the prostate cancer cell line DU145 to ionizing radiation. , 2012, Biochemical and biophysical research communications.

[68]  S. Peters,et al.  MET: a promising anticancer therapeutic target , 2012, Nature Reviews Clinical Oncology.

[69]  S. Powell,et al.  BRCA1 and BRCA2: important differences with common interests , 2012, Nature Reviews Cancer.

[70]  M. Resnick,et al.  Differential effects of poly(ADP-ribose) polymerase inhibition on DNA break repair in human cells are revealed with Epstein–Barr virus , 2012, Proceedings of the National Academy of Sciences.

[71]  Shinji Yamazaki,et al.  Sensitivity of Selected Human Tumor Models to PF-04217903, a Novel Selective c-Met Kinase Inhibitor , 2012, Molecular Cancer Therapeutics.

[72]  Ji‐you Li,et al.  Value of c-Met for predicting progression of precancerous gastric lesions in rural Chinese population , 2012, Chinese journal of cancer research = Chung-kuo yen cheng yen chiu.

[73]  D. Aebersold,et al.  MET inhibition in tumor cells by PHA665752 impairs homologous recombination repair of DNA double strand breaks , 2012, International journal of cancer.

[74]  Ming-Sound Tsao,et al.  An overview of the c-MET signaling pathway , 2011, Therapeutic advances in medical oncology.

[75]  Zhihui Feng,et al.  A dual role of BRCA1 in two distinct homologous recombination mediated repair in response to replication arrest , 2011, Nucleic acids research.

[76]  Thomas Helleday,et al.  The underlying mechanism for the PARP and BRCA synthetic lethality: Clearing up the misunderstandings , 2011, Molecular oncology.

[77]  E. Medico,et al.  Induction of MET by ionizing radiation and its role in radioresistance and invasive growth of cancer. , 2011, Journal of the National Cancer Institute.

[78]  Shridar Ganesan,et al.  BRCA1, PARP, and 53BP1: conditional synthetic lethality and synthetic viability. , 2011, Journal of molecular cell biology.

[79]  S. Aebi,et al.  MET Inhibition Results in DNA Breaks and Synergistically Sensitizes Tumor Cells to DNA-Damaging Agents Potentially by Breaching a Damage-Induced Checkpoint Arrest. , 2010, Genes & cancer.

[80]  M. Karamouzis,et al.  DNA repair pathways and their implication in cancer treatment , 2010, Cancer and Metastasis Reviews.

[81]  M. Shin,et al.  BRCA1 and XRCC1 polymorphisms associated with survival in advanced gastric cancer treated with taxane and cisplatin , 2010, Cancer science.

[82]  S. Ogawa,et al.  Gastric cancer cell line Hs746T harbors a splice site mutation of c-Met causing juxtamembrane domain deletion. , 2010, Biochemical and biophysical research communications.

[83]  J. Welsh,et al.  The c-Met receptor tyrosine kinase inhibitor MP470 radiosensitizes glioblastoma cells , 2009, Radiation oncology.

[84]  M. Karamouzis,et al.  Targeting MET as a strategy to overcome crosstalk-related resistance to EGFR inhibitors. , 2009, The Lancet. Oncology.

[85]  Christopher K. Glass,et al.  Tyrosine Dephosphorylation of H2AX Modulates Apoptosis and Survival Decisions , 2009, Nature.

[86]  Paul Tempst,et al.  WSTF regulates the function of H2A.X via a novel tyrosine kinase activity , 2008, Nature.

[87]  S. Jackson,et al.  Targeting DNA Repair in Cancer: Beyond PARP Inhibitors. , 2017, Cancer discovery.

[88]  T. Skorski,et al.  Targeting BRCA1- and BRCA2-deficient cells with RAD52 small molecule inhibitors , 2016, Nucleic acids research.

[89]  A. D’Andrea,et al.  Repair Pathway Choices and Consequences at the Double-Strand Break. , 2016, Trends in cell biology.

[90]  J. Yélamos,et al.  PARP-1 and PARP-2: New players in tumour development. , 2011, American journal of cancer research.